MORRISVILLE, N.C.--(BUSINESS WIRE)--Arrivo BioVentures today announced preliminary results from its SP-624-201 study, a randomized, placebo-controlled Phase 2 clinical trial of SP-624 in 319 patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback